• OPEN AN ACCOUNT
Indian Indices
Nifty
22,475.85 -172.35
(-0.76%)
Sensex
73,878.15 -732.96
( -0.98%)
Bank Nifty
48,923.55 -307.50
( -0.62%)
Nifty IT
32,908.40 -294.95
( -0.89%)
Global Indices
Nasdaq
15,840.96 235.48
(1.51%)
Dow Jones
38,225.66 322.37
(0.85%)
Hang Seng
18,475.92 268.79
(1.48%)
Nikkei 225
38,236.07 -37.98
(-0.10%)
Forex
USD-INR
83.46 0.03
(0.03%)
EUR-INR
89.11 -0.30
(-0.33%)
GBP-INR
104.27 -0.36
(-0.34%)
JPY-INR
0.53 0.00
(-0.39%)

EQUITY - MARKET SCREENER

Hero MotoCorp Ltd
Industry :  Automobiles - Motorcycles / Mopeds
BSE Code
ISIN Demat
Book Value()
500182
INE158A01026
894.9499068
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
HEROMOTOCO
23.2
91213.29
EPS(TTM)
Face Value()
Div & Yield %
196.65
2
2.19
 

Dr Reddys Laboratories Ltd
Dr Reddys launches migraine management wearable device Nerivio® in Germany
Apr 10,2024

Dr. Reddy's Laboratories announced the launch of the drug-free non-invasive migraine management wearable device Nerivio® in Germany through its step-down subsidiary betapharm. The launch marks the company's entry into digital therapeutics in Europe. Nerivio® is approved by the United States Food and Drug Administration (USFDA), and is CE-mark certified in Europe.

Nerivio® was presented in 2023 by Dr. Reddy's at the DGN Kongress organised by the German Association of Neurology in Berlin, and the 17th European Headache Congress held in Barcelona, Spain. Dr. Reddy's will present and launch Nerivio® during the Neurological Association of South Africa annual congress on April 17, 2024, in the presence of Dr. Stewart Tepper, Professor of Neurology at the Geisel School of Medicine – Dartmouth, and Vice President, New England Institute for Neurology and Headache. In May 2024, Nerivio® will also be presented at International Headache Society 2024 iHEAD meeting in Berlin, Germany. In subsequent months, Dr. Reddy's will launch Nerivio® in Spain and the UK.

Last year, Dr. Reddy's entered into an exclusive agreement with Theranica, a prescribed digital therapeutics company developing advanced neuromodulation devices for migraine and other pain conditions, for the marketing and distribution of Nerivio® in multiple markets.

Dr. Reddy's launched Nerivio® in India in 2023. In India, Nerivio® is supported by Dr. Reddy's unique patient support programme called ‘M-Free'. The programme is a comprehensive support system that enhances and streamlines the journey of the patients. M-Free includes services such as onboarding and counseling of patients, device demonstrations, doorstep delivery, flexible payment options, informative content, and dedicated customer care to help patients get the most out of the device. With lifestyle modification as a key recommendation for better management of migraine, M-Free awareness program offers a suite of value-add services such as nutritionist consultation, yoga and meditation sessions with certified specialists for holistic medicine free migraine management.